Ravi Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.50 M
as on 16-11-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 1560.36%
(FY 2023)
- Profit 8604.54%
(FY 2023)
- Ebitda -5.44%
(FY 2023)
- Net Worth 56.77%
(FY 2023)
- Total Assets 238.01%
(FY 2023)
About Ravi Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Vinod Singhania, Harshvardhan Singhania, and Devang Singhania serve as directors at the Company.
- CIN/LLPIN
U74999MH2018PTC313211
- Company No.
313211
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ravi Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harshvardhan Singhania  | Director | 29-Aug-2018 | Current |
| Vinod Singhania | Director | 29-Aug-2018 | Current |
| Devang Singhania | Director | 29-Aug-2018 | Current |
Financial Performance and Corporate Structure Insights of Ravi Lifesciences.
Ravi Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1560.36% increase. The company also saw a substantial improvement in profitability, with a 8604.54% increase in profit. The company's net worth Soared by an impressive increase of 56.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ravi Lifesciences?
In 2023, Ravi Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Siddharth Colorchem Private LimitedActive 37 years 9 monthsVinod Singhania and Devang Singhania are mutual person
Ravi Biolife Private LimitedActive 3 years 11 monthsVinod Singhania and Devang Singhania are mutual person
_PRIVATE_LIMITED.webp)
Melody Healthcare Private LimitedActive 18 years 4 monthsVinod Singhania, Harshvardhan Singhania and 1 more are mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ravi Lifesciences?
Unlock and access historical data on people associated with Ravi Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ravi Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ravi Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
